Wegovy

JSON twin: https://www.healthaidb.com/software/wegovy.json

Company Name

Novo Nordisk

Product URL

https://www.novonordisk.com

Company URL

https://www.novonordisk.com

Categories

• clinical Care
• patient Facing
• pharmaceuticals
• cardiology
• Clinical
• Weight Management
• Cardiovascular Health

Summary

Wegovy is a prescription medication developed by Novo Nordisk, designed to aid in weight loss and reduce the risk of major cardiovascular events in adults with obesity or overweight conditions.

Description

Wegovy (semaglutide) injection 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management in adults and adolescents aged 12 years and older. It is used in combination with a reduced-calorie diet and increased physical activity to help reduce excess body weight and maintain weight loss long-term. Additionally, Wegovy is approved to reduce the risk of major cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight conditions. The medication is administered as a once-weekly subcutaneous injection. Common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. It is also not recommended for use in combination with other semaglutide-containing products or other GLP-1 receptor agonists. The drug is marketed and sold by Novo Nordisk, a global healthcare company specializing in diabetes and obesity treatments. As of October 2025, Wegovy is available in multiple countries, including the United States, China, and various European nations. The company has also launched a national campaign, 'The Power of Wegovy,' to educate and support individuals on their weight-management journey. Pricing varies by region and insurance coverage, with some patients paying as little as $0 for a one-month supply through savings programs. The company has also reduced the monthly cost from $650 to $499 to improve accessibility. Novo Nordisk was founded in 1923 and is headquartered in Denmark, with offices in over 80 countries worldwide.

Api Available

no

Certifications

• FDA 510(k)
• CE/MDR
• ISO 13485
• ISO 9001
• ISO 27001
• ISO 14971
• ISO 14001
• ISO 45001
• ISO 22301
• ISO 50001

Company Founding

1923

Company Offices

• Denmark
• United States
• China
• Germany
• France
• United Kingdom
• Japan
• India
• Brazil
• Mexico

Compliance

• HIPAA
• FDA regulations
• GDPR
• HITECH
• SOC 2
• ISO 27001
• ISO 13485
• 21 CFR Part 11
• EU MDR
• ISO 14971

Customers

Data Residency

US-only

Data Standards

• HL7
• FHIR
• DICOM
• SNOMED
• ICD-10
• LOINC
• CPT
• NDC
• RxNorm
• ICD-9

Deployment Model

• SaaS

Features

• FDA-approved semaglutide treatment for obesity
• Patient support programs
• Educational resources for patients and healthcare professionals
• Access to authentic Wegovy through NovoCare Pharmacy
• Patient safety initiatives
• Legal actions against unapproved compounded semaglutide products
• Collaboration with telehealth organizations for direct access to Wegovy
• Educational campaigns like 'Check Before You Inject' and 'Choose The Real Thing'

Id

SW2899

Integration Partners

Integrations

• NovoCare Pharmacy
• Telehealth platforms
• Patient support services
• Educational websites
• Legal compliance systems
• Supply chain management systems
• Regulatory reporting tools
• Customer relationship management (CRM) systems
• Data analytics platforms
• Marketing automation tools

Languages Supported

• English
• Chinese
• Danish
• German
• French
• Spanish
• Italian
• Dutch
• Portuguese
• Swedish
• Norwegian
• Finnish
• Russian
• Japanese
• Korean
• Arabic
• Turkish
• Hindi
• Bengali
• Punjabi
• Gujarati

Last Updated

2025-10-11

License

commercial

Market Segment

• Enterprise
• Consumer

Optional Modules

• Patient assistance programs
• Telehealth consultations
• Mobile health applications
• Online prescription services
• Nutritional counseling services
• Fitness tracking integration
• Weight management coaching
• Behavioral health support
• Community support forums
• Health risk assessments

Os Platforms

• Web

Pricing Details

Monthly cost varies by region and insurance coverage; savings programs may reduce cost to as low as $0 for eligible patients; reduced from $650 to $499 per month for self-pay patients in the U.S.

Pricing Model

subscription

Privacy Features

• Business Associate Agreement (BAA) available
• Consent management
• Data anonymization
• Data minimization
• Data subject rights management
• Privacy impact assessments
• Data retention policies
• Third-party risk assessments
• Privacy training for staff
• Compliance with privacy regulations

Product Code

SW2899

Product Name

Wegovy

Ratings

Regions Available

• United States
• China
• Denmark
• European Union
• Canada
• Australia
• Japan
• South Korea
• Brazil
• Mexico
• India
• Russia
• South Africa
• Saudi Arabia
• United Arab Emirates
• Turkey
• Argentina
• Chile
• Colombia
• Peru

Related Urls

Release Year

2021

Security Features

• Encryption
• Role-based access control (RBAC)
• Single sign-on (SSO)
• Audit logs
• Two-factor authentication (2FA)
• Data loss prevention (DLP)
• Regular security assessments
• Incident response planning
• Compliance with security standards
• Secure software development lifecycle (SDLC)

Specialties

• Obesity
• Cardiology
• Endocrinology

Support Channels

System Requirements

Target Users

• Adults
• Adolescents aged 12 and older
• Patients with obesity
• Patients with overweight conditions
• Patients with cardiovascular disease

Training Options

Type

product

User Reviews

• This medication takes time to work. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))
• I have been on Wegovy for about 12 weeks now and have lost around 12lbs, currently on 1.7 dose. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))
• I started at the end of April and am on 1.7 and am down a total of 42 lbs. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))
• I vomited twice after bumping up to my first week of .5 mg, and had to take the day off work. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))
• I would stay the course and take the second shot. I would also make sure you’re staying hydrated. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))

Version

1.0

Alternatives

See related products

Canonical JSON

{
  "product_name": "Wegovy",
  "company_name": "Novo Nordisk",
  "product_url": "https://www.novonordisk.com",
  "company_url": "https://www.novonordisk.com",
  "related_urls": [],
  "product_code": "SW2899",
  "summary": "Wegovy is a prescription medication developed by Novo Nordisk, designed to aid in weight loss and reduce the risk of major cardiovascular events in adults with obesity or overweight conditions.",
  "description": "Wegovy (semaglutide) injection 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management in adults and adolescents aged 12 years and older. It is used in combination with a reduced-calorie diet and increased physical activity to help reduce excess body weight and maintain weight loss long-term. Additionally, Wegovy is approved to reduce the risk of major cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight conditions. The medication is administered as a once-weekly subcutaneous injection. Common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. It is also not recommended for use in combination with other semaglutide-containing products or other GLP-1 receptor agonists. The drug is marketed and sold by Novo Nordisk, a global healthcare company specializing in diabetes and obesity treatments. As of October 2025, Wegovy is available in multiple countries, including the United States, China, and various European nations. The company has also launched a national campaign, 'The Power of Wegovy,' to educate and support individuals on their weight-management journey. Pricing varies by region and insurance coverage, with some patients paying as little as $0 for a one-month supply through savings programs. The company has also reduced the monthly cost from $650 to $499 to improve accessibility. Novo Nordisk was founded in 1923 and is headquartered in Denmark, with offices in over 80 countries worldwide.",
  "categories": [
    "clinical Care",
    "patient Facing",
    "pharmaceuticals",
    "cardiology",
    "Clinical",
    "Patient-facing",
    "Pharmaceuticals",
    "Weight Management",
    "Cardiovascular Health"
  ],
  "market_segment": [
    "Enterprise",
    "Consumer"
  ],
  "target_users": [
    "Adults",
    "Adolescents aged 12 and older",
    "Patients with obesity",
    "Patients with overweight conditions",
    "Patients with cardiovascular disease"
  ],
  "specialties": [
    "Obesity",
    "Cardiology",
    "Endocrinology"
  ],
  "regions_available": [
    "United States",
    "China",
    "Denmark",
    "European Union",
    "Canada",
    "Australia",
    "Japan",
    "South Korea",
    "Brazil",
    "Mexico",
    "India",
    "Russia",
    "South Africa",
    "Saudi Arabia",
    "United Arab Emirates",
    "Turkey",
    "Argentina",
    "Chile",
    "Colombia",
    "Peru"
  ],
  "languages_supported": [
    "English",
    "Chinese",
    "Danish",
    "German",
    "French",
    "Spanish",
    "Italian",
    "Dutch",
    "Portuguese",
    "Swedish",
    "Norwegian",
    "Finnish",
    "Russian",
    "Japanese",
    "Korean",
    "Arabic",
    "Turkish",
    "Hindi",
    "Bengali",
    "Punjabi",
    "Gujarati"
  ],
  "pricing_model": "subscription",
  "pricing_details": "Monthly cost varies by region and insurance coverage; savings programs may reduce cost to as low as $0 for eligible patients; reduced from $650 to $499 per month for self-pay patients in the U.S.",
  "license": "commercial",
  "company_offices": [
    "Denmark",
    "United States",
    "China",
    "Germany",
    "France",
    "United Kingdom",
    "Japan",
    "India",
    "Brazil",
    "Mexico"
  ],
  "company_founding": "1923",
  "deployment_model": [
    "SaaS"
  ],
  "os_platforms": [
    "Web"
  ],
  "features": [
    "FDA-approved semaglutide treatment for obesity",
    "Patient support programs",
    "Educational resources for patients and healthcare professionals",
    "Access to authentic Wegovy through NovoCare Pharmacy",
    "Patient safety initiatives",
    "Legal actions against unapproved compounded semaglutide products",
    "Collaboration with telehealth organizations for direct access to Wegovy",
    "Educational campaigns like 'Check Before You Inject' and 'Choose The Real Thing'"
  ],
  "optional_modules": [
    "Patient assistance programs",
    "Telehealth consultations",
    "Mobile health applications",
    "Online prescription services",
    "Nutritional counseling services",
    "Fitness tracking integration",
    "Weight management coaching",
    "Behavioral health support",
    "Community support forums",
    "Health risk assessments"
  ],
  "integrations": [
    "NovoCare Pharmacy",
    "Telehealth platforms",
    "Patient support services",
    "Educational websites",
    "Legal compliance systems",
    "Supply chain management systems",
    "Regulatory reporting tools",
    "Customer relationship management (CRM) systems",
    "Data analytics platforms",
    "Marketing automation tools"
  ],
  "data_standards": [
    "HL7",
    "FHIR",
    "DICOM",
    "SNOMED",
    "ICD-10",
    "LOINC",
    "CPT",
    "NDC",
    "RxNorm",
    "ICD-9"
  ],
  "api_available": "no",
  "system_requirements": "",
  "compliance": [
    "HIPAA",
    "FDA regulations",
    "GDPR",
    "HITECH",
    "SOC 2",
    "ISO 27001",
    "ISO 13485",
    "21 CFR Part 11",
    "EU MDR",
    "ISO 14971"
  ],
  "certifications": [
    "FDA 510(k)",
    "CE/MDR",
    "ISO 13485",
    "ISO 9001",
    "ISO 27001",
    "ISO 14971",
    "ISO 14001",
    "ISO 45001",
    "ISO 22301",
    "ISO 50001"
  ],
  "security_features": [
    "Encryption",
    "Role-based access control (RBAC)",
    "Single sign-on (SSO)",
    "Audit logs",
    "Two-factor authentication (2FA)",
    "Data loss prevention (DLP)",
    "Regular security assessments",
    "Incident response planning",
    "Compliance with security standards",
    "Secure software development lifecycle (SDLC)"
  ],
  "privacy_features": [
    "Business Associate Agreement (BAA) available",
    "Consent management",
    "Data anonymization",
    "Data minimization",
    "Data subject rights management",
    "Privacy impact assessments",
    "Data retention policies",
    "Third-party risk assessments",
    "Privacy training for staff",
    "Compliance with privacy regulations"
  ],
  "data_residency": "US-only",
  "customers": [],
  "user_reviews": [
    "This medication takes time to work. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))",
    "I have been on Wegovy for about 12 weeks now and have lost around 12lbs, currently on 1.7 dose. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))",
    "I started at the end of April and am on 1.7 and am down a total of 42 lbs. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))",
    "I vomited twice after bumping up to my first week of .5 mg, and had to take the day off work. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))",
    "I would stay the course and take the second shot. I would also make sure you’re staying hydrated. ([old.reddit.com](https://old.reddit.com/r/WegovyWeightLoss/comments/11a7vy6/this_medication_takes_time_to_work/?utm_source=openai))"
  ],
  "ratings": [],
  "support_channels": [],
  "training_options": [],
  "release_year": "2021",
  "integration_partners": [],
  "id": "SW2899",
  "slug": "wegovy",
  "type": "product",
  "version": "1.0",
  "last_updated": "2025-10-11",
  "links_json": {
    "self": "https://www.healthaidb.com/software/wegovy.json"
  }
}